Screener
Immunome IMNM Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $5.01M+62.5% | $5.49M+83.3% | $2.96M+8.8% | $2.68M-21.7% | $3.08M-20.7% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $4.02M+69.8% | ||
| $59.89M+48.0% | $46.38M+25.8% | $50.77M+6.0% | $49.19M+32.2% | $40.45M+39.1% | ||
| $18.25M+81.7% | $12.95M+21.1% | $12.09M+15.7% | $10.95M+14.9% | $10.04M+43.9% | ||
| $78.14M+54.7% | $59.33M+24.7% | $72.86M-15.0% | $60.14M+12.6% | $50.49M+19.2% | ||
| -$78.14M-68.1% | -$59.33M-32.9% | -$72.86M+12.2% | -$60.14M-19.0% | -$46.48M-16.2% | ||
| -$73.13M-68.5% | -$53.84M-29.3% | -$69.9M+12.9% | -$57.46M-22.0% | -$43.4M-20.1% | ||
| -$0.65-30.0% | -$0.48+7.7% | -$0.75+41.4% | -$0.65+16.7% | -$0.50+16.7% | ||
| -$77.18M-68.4% | -$58.73M-33.4% | -$72.23M+12.5% | -$59.55M-18.8% | -$45.84M-16.2% | ||
| -$78.14M-68.1% | -$59.33M-32.9% | -$72.86M+12.2% | -$60.14M-19.0% | -$46.48M-16.2% |
FAQ
- Is Immunome profitable?
- Immunome is not currently profitable: it reported a net loss of $254.3M over the trailing twelve months, a -5593.8% net margin.
- What is Immunome's earnings per share?
- Immunome's diluted EPS over the trailing twelve months is $-2.53.
- Where does Immunome's income statement data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.